Prevention of VTE in orthopedic surgery patients
DOI:
https://doi.org/10.7175/fe.v14i2S.881Keywords:
New oral anticoagulants, Deep vein thrombosis, HTA, Low Molecular Weight HeparinAbstract
Venous thromboembolism (VTE) is defined as the obstruction, partial or complete, of one or more veins of deep circulation. It is a condition that can lead to a deterioration in his state of health until death, manifesting as deep vein thrombosis (DVT) or pulmonary embolism (PE). The major orthopedic surgery and the surgical oncology are frequently associated with thromboembolic complications, because of conditions that are often critical in these patients. It is estimated that in Italy DVT has an incidence that varies between 50 and 150 new cases per 100,000 population, while the prevalence would be between 2.5 and 5%. In the absence of thromboprophylaxis, the orthopedic surgery lead to a high increased risk of VTE. In elective hip replacement, in the absence of prophylaxis, the incidence of DVT and of fatal PE is about 50% and 2% respectively. In elective knee arthroplasty the risk of venous thromboembolic complications is even higher. It is estimated that 56.2% of the costs of prophylaxis with Low Molecular Weight Heparin (LMWH) in patients undergoing major orthopedic surgery are attributable to the cost of drugs (about € 200), followed (with 44.8%) by the cost of administration (approximately € 159). The average total cost/day was estimated at € 8 per patient. In Italy, it has been estimated an annual cost for new cases between 215 and 260 million €. The clinical advantages of the New Oral Anticoagulants (NOA) appear to be substantially clear, the major concern with regard to their reimbursement is therefore linked to the financial impact, due to the higher cost per day of the NOA compared with LMWH. To this end, it was built a model of budget impact, in the perspective of the Italian NHS, from the data related to cases of major surgical orthopedic procedures and a meta-analysis on the pivotal RCT, which aims to measure the differential effects in terms of prevention of VTE. The results show that the financial impact of the NOA in the prophylaxis of major orthopedic surgery is not particularly relevant. In fact, the major pharmaceutical costs that, at national level, amount to € 10.8 mil. (€ 15.2 mil. in the case of prolonged prophylaxis in knee operations) would be more than offset by savings in terms of fewer treatments of VTE, which is based on the assumption of more than 4,000 cases, up to about 6,600 in hypothesis best efficacy.
References
CADTH – Canadian Agency for Drugs and Technologies in Health. Dabigatran or Rivaroxaban Versus Other Anticoagulants for Thromboprophylaxis After Major Orthopedic Surgery: Systematic Review of Comparative Clinical-Effectiveness and Safety. CADTH Technol Overv 2010; 1: e0111
Di Minno M, Tufano A, Pilotto A, et al. Prevenzione del tromboembolismo venoso nell’anziano nel 2007: nuove strategie antitrombotiche nel paziente medico e chirurgico. G Gerontol 2007; 55: 40-7
Browse NL, Burnand KG, Irvine AT, et al. (eds). Disease of the Veins. 2nd ed. London: Arnold, 1999
Torbicki A, Van Beek EJ, Charbonnier B. Guidelines on diagnosis and management of acute pulmonary embolism. The Task Force on Pulmonary Embolism, European Society of Cardiology. Eur Heart J 2000; 21: 1301-36; http://dx.doi.org/10.1053/euhj.2000.2250
Mandelli V, Schmid C, Zogno C, et al. “False negatives” and “false positives” in acute pulmonary embolism: a clinical-postmortem comparison. Cardiologia 1997; 42: 205-10
Geerts WH, Pineo GF, Heit JA, et al. Prevention of Venous Thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy, Chest 2004; 126; 338S-400S; http://dx.doi.org/10.1378/chest.126.3_suppl.338S
Ministero della salute, Banca dati SDO, 2010
Fattore G, Colangelo I, Martelli E, et al. Metodi e costi della profilassi della trombosi venosa profonda in chirurgia ortopedica in Italia. PharmacoEconomics - Italian Research Articles 2004; 6: 69-80
Cohen A, Tapson V, Bergmann J. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 2008; 371: 387-94; http://dx.doi.org/10.1016/S0140-6736(08)60202-0
Levy E, Gabriel S, Dinet J, et al. Assessing the total cost of management of a patient with deep vein thrombosis (DVT) in France and Italy. Value Health 2001; 4: 102; http://dx.doi.org/10.1046/j.1524-4733.2001.40202-94.x
Caprini JA, Botteman MF, Stephens JM, et al. Economic burden of long-term complications of deep vein thrombosis after total hip replacement surgery in the United States. Value Health 2003; 6: 59-74; http://dx.doi.org/10.1046/j.1524-4733.2003.00204.x
Oster G, Ollendorf DA, Vera-Llonch M, et al. Economic consequences of venous thromboembolism following major orthopedic surgery. Ann Pharmacother 2004; 38: 377-82; http://dx.doi.org/10.1345/aph.1C518
Ollendorf DA, Vera-Llonch M, Oster G. Cost of venous thromboembolism following major orthopedic surgery in hospitalized patients. Am J Health Syst Pharm 2002; 59: 1750-54
McBride D, Brüggenjürgen B, Roll S, et al. Management pattern of thrombosis prophylaxis and related costs in hip and knee replacement in Germany. Cent Eur J Med 2007; 2; 47-65; http://dx.doi.org/10.2478/s11536-007-0005-7
Leizorovicz A. Long-term consequences of deep vein thrombosis. Haemostasis 1998; 28 Suppl 3: 1-7
Pengo V, Lensing AW, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004; 350: 2257-64; http://dx.doi.org/10.1056/NEJMoa032274
Capri S, Ageno W, Imberti D, et al. Extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy: a cost-effectiveness analysis. Intern Emerg Med 2010; 5: 33-40; http://dx.doi.org/10.1007/s11739-009-0324-6
National Institute for Health and Clinical Excellence. Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in inpatients undergoing surgery, 2007 (NICE clinical guideline No. 46.)
White RH, Romano PS, Zhou H, et al. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 1998; 158: 1525-31; http://dx.doi.org/10.1001/archinte.158.14.1525
Imberti D, Bianchi C, Zambon A, et al. Venous thromboembolism after major orthopaedic surgery: a population-based cohort study. Intern Emerg Med 2012; 7: 243-9; http://dx.doi.org/10.1007/s11739-011-0567-x
LazioSanità – Agenzia di Sanità Pubblica. Profilassi della tromboembolia venosa post-chirurgica, 2007
Geerts WH, Bergqvist D, Pineo GF, et al.; American College of Chest Physicians. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133(6 Suppl): 381S-453S; http://dx.doi.org/10.1378/chest.08-0656
Creekmore FM, Oderga GM, Pendleton RC, et al. Incidence and economic implication of heparin-induced thrombocytopenia in medical patients receiving prophylaxis for venous thromboembolism. Pharmacoterapy 2006; 26: 1438-45; http://dx.doi.org/10.1592/phco.26.10.1438
Centro di Riferimento Regionale sul Farmaco della Regione Veneto. Realizzare valutazioni di HTA. La valutazione dei farmaci, 2009
Della Rocca G, Biggi F, Grossi P, et al. Italian intersociety consensus statement on antithrombotic prophylaxis in hip and knee replacement and in femoral neck fracture surgery. Minerva Anestesiologica 2011; 77: 1003-10
Eriksson BI, Dahl OE, Rosencher N, et al.; RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial, Lancet 2007; 370: 949-56; http://dx.doi.org/10.1016/S0140-6736(07)61445-7
Eriksson BI, Dahl OE, Rosencher N, et al.; RE-MODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 5: 2178-85; http://dx.doi.org/10.1111/j.1538-7836.2007.02748.x
Eriksson BI, Dahl OE, Huo MH, et al., for the RE-NOVATE II Study Group. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised,double-blind, non-inferiority trial, Thromb Haemost 2011; 105: 721-729; http://dx.doi.org/10.1160/TH10-10-0679
Eriksson BI, Borris LC, Friedman RJ, et al.; RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765-75; http://dx.doi.org/10.1056/NEJMoa0800374
Kakkar AK, Brenner B, Dahl OE, et al.; RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomized controlled trial. Lancet 2008; 372: 31-9; http://dx.doi.org/10.1016/S0140-6736(08)60880-6
Lassen MR, Ageno W, Borris LC, et al.; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 2776-86; http://dx.doi.org/10.1056/NEJMoa076016
Lassen MR, Raskob GE, Gallus A, et al.; ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010; 375: 807-15; http://dx.doi.org/10.1016/S0140-6736(09)62125-5
Lassen MR, Gallus A, Raskob GE, et al.; ADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010; 363: 2487-98; http://dx.doi.org/10.1056/NEJMoa1006885
Maratea D, Fadda V, Trippoli S, et al. Prevention of venous thromboembolism after major orthopedic surgery: indirect comparison of three new oral anticoagulants. J Thromb Haemost 2011; 9: 1868-70; http://dx.doi.org/10.1111/j.1538-7836.2011.04421.x.
National Institute for Health and Clinical Excellence – NICE. Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults, 2008(NICE technology appraisal guidance 157)
National Institute for Health and Clinical Excellence – NICE. Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults, 2009 (NICE technology appraisal guidance 170)
National Institute for Health and Clinical Excellence – NICE. Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults, 2012 (NICE technology appraisal guidance 245)
Wolowacz SE, Roskell, NS, Maciver F, et al. Economic Evaluation of Dabigatran Etexilate for the Prevention of Venous Thromboembolism After Total Knee and Hip Replacement Surgery. Clin Ther 2009, 31: 194-212; http://dx.doi.org/10.1016/j.clinthera.2009.01.001
Gonzalez-Rojas N, Vieta A, Monreal M, et al. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism following total hip and knee replacement in Spain. Value in Health 2009; 12: A440; http://dx.doi.org/10.1016/S1098-3015(10)75177-9
Boersma C, Kappelhoff BS, Postma MJ. Dabigatran etexilate is cost-saving for the primary prevention of venous thromboembolic events following major orthopaedic surgery in the Netherlands. Value in Healh 2009; 12: A334; http://dx.doi.org/10.1016/S1098-3015(10)74641-6
Duggan ST, Scott LJ, Plosker GL. Rivaroxaban. A Review of its Use for the Prevention of Venous Thromboembolism After Total Hip or Knee Replacement Surgery. Drugs 2009; 69: 1829-51; http://dx.doi.org/10.2165/11200890-000000000-00000
Diamantopoulos A, Lees M, Wells PS, et al. Cost-Effectiveness of Rivaroxaban versus Enoxaparin for the Prevention of Postsurgical Venous Thromboembolism in Canada. Thromb Haemost 2010; 104: 760-70; http://dx.doi.org/10.1160/TH10-01-0071
McCullagh L, Tilson L, Walsh C, et al. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting. Pharmacoeconomics 2009; 27: 829-46; http://dx.doi.org/10.2165/11313800-000000000-00000
Dabigatran – Riassunto delle Caratteristiche di Prodotto
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).
- Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)
